Mydayis FDA Approval History
Last updated by Judith Stewart, BPharm on April 9, 2021.
FDA Approved: Yes (First approved June 20, 2017)
Brand name: Mydayis
Generic name: amphetamine mixed salts
Company: Shire plc
Treatment for: Attention Deficit Hyperactivity Disorder (ADHD)
Mydayis (amphetamine mixed salts) is a central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients 13 years and older.
Development timeline for Mydayis
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.